www.lifesciencesipreview.com

Life Sciences IP Review

17,000+ key IP decision-makers rely on Life Sciences IP Review (LSIPR) as their daily source of news in the life sciences, biotechnology and pharmaceutical industry.

LSIPR offers IP professionals a single point of contact to stay on top of industry trends and developments. No other online platform offers such in-depth or comprehensive analysis of the latest IP news in the life sciences, with:

  • A quarterly e-magazine covering key industry events;
  • Daily online news updates published on www.lifesciencesipreview.com;
  • Special reports and whitepapers on trending topics;
  • Bi-weekly e-newsletters covering relevant industry developments;
  • Virtual webinars and in-person conferences; and
  • An online community for IP professionals to grow their expertise and expand their professional network.

Readers of LSIPR include IP professionals from leading global organisations such as: Novartis, Johnson & Johnson, Astra Zeneca, Teva, Boeringher Ingelheim, Pfizer, Alnylam Pharmaceuticals, Astellas Pharma, Genentech, Millipore Sigma, GSK, Prolacta Bioscience, Amunix Pharmaceuticals, BioInfi, Merck and more.

LSIPR is the go-to resource for any IP professional practising in the life sciences sector. To access our quarterly e-magazine, daily news articles or to learn more about upcoming events, visit our website: www.lifesciencesipreview.com.

To sign up to receive our free e-newsletter, covering the latest industry news – click here: https://pages.services/info.lifesciencesipreview.com/lsipr-newsletter-sign-up

Follow LSIPR on social media: